Cyrus Biotechnology Products, Competitors and Risks - aVenture
Cyrus Biotechnology
Cyrus Biotechnology is a Seattle-based computational protein design company that engineers biologics from natural proteins for therapeutic indications.
Cyrus pairs proprietary computational design with in-house experimental deep mutational scanning, allowing candidate engineering to be validated quantitatively rather than predicted only in silico.
This hybrid approach supports reduced immunogenicity, extended serum half-life, and improved stability and solubility, as demonstrated by engineered IgG protease variants such as CYR212 and CYR241.
Cyrus Biotechnology's lead protease program targets chronic IgG-driven autoimmune diseases including myasthenia gravis and immune thrombocytopenia, where depletion of pathogenic IgG addresses the underlying disease mechanism.
In January 2025 the company announced CYR212 as its clinical development candidate, and the engineered protease is also positioned to deplete IgG ahead of AAV-mediated gene therapy delivery, extending the addressable market.
Cyrus Biotechnology offers a computational protein design platform that combines AI and Rosetta-based design methods with a laboratory specializing in quantitative, large-scale mutagenesis scanning.
The platform is used to engineer biologics for immunogenicity reduction, half-life extension, stability, solubility, and affinity optimization, and it has been applied across dozens of partnered discovery programs with pharmaceutical and biotechnology partners.
